as the healthcare sector. However, GlaxoSmithKline (NYSE: GSK ) has been suffering due to some issues in China and poor performance ..... climb up again due to recent FDA drug approvals. Moreover, GSK 's deal with Novartis (NYSE: NVS ) has improved the cash position
publicly traded drug manufacturer in the world, behind giants such as AstraZeneca (NYSE: AZN ), GlaxoSmithKline (NYSE: GSK ), and Pfizer (NYSE: PFE ). Humira Is AbbVie's Biggest Winner AbbVie generated 67% of its 2nd-quarter sales from its
Ebola Vaccine in Preclinicals; BioCryst Pharmaceuticals (NASDAQ: BCRX ): BCX4430 in Preclinicals; GlaxoSmithKline (NYSE: GSK ): Ebola Vaccine in Preclinicals; Nanoviricides (NYSEMKT: NNVC ): NV-INF-1 in Preclinicals; Inovio Pharmaceuticals
* Trials to vaccinate healthy volunteers from mid-September
By Wall Street Breakfast : Economy In a grudging first step towards opening its state-dominated oil sector, China has granted a crude import license to non-state-owned Guanghui Energy. China's Ministry of Commerce stopped short of truly opening the market, since the new license does not actively ...
LONDON, Aug 28 (Reuters) - An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build up a stockpile of up to 10,000 doses for emergency deployment, if results are good.
announcement by U.S. health officials today will state that a human study for the Ebola vaccine made by GlaxoSmithKline (NYSE: GSK ) will begin within a couple of weeks instead of later this year as the company originally estimated. Glaxo's vaccine contains
NEW YORK, Aug 27 (Reuters) - U.S. health officials will announce on Thursday that a human study of an Ebola vaccine made by GlaxoSmithKline will begin within a couple of weeks and not later this year as the company estimated originally, according to people familiar with the plans.
the deadly ebola virus. Rumors suggest interested parties could include Shire (NASDAQ: SHPG ) and GlaxoSmithKline (NYSE: GSK ); the report suggests the recent premium paid for InterMune could put a valuation of at least $40/share on TKMR. Post your
By IAEResearch : The healthcare sector has been performing well over the last few months - in fact, most of the BioPharma companies have outperformed most of the sectors and the overall market itself. However, some of the major players have not been able to show the same price movement - Pfizer ...